Cellectis (CLLS) Reiterated at Market Outperform by Citizens: 2025 Pipeline Updates Good

March 23, 2026 4:46 AM

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $8.00 price target on Cellectis (NASDAQ: CLLS).The analyst commented, "Cellectis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found